Mitochondria have emerged as important pharmacological targets because of their key role in cellular proliferation and death. In tumor tissues, mitochondria can switch metabolic phenotypes to meet the challenges of high energy demand and macromolecular synthesis. Furthermore, mitochondria can engage in crosstalk with the tumor microenvironment, and signals from cancer-associated fibroblasts can impinge on mitochondria. Cancer cells can also acquire a hybrid phenotype in which both glycolysis and oxidative phosphorylation (OXPHOS) can be utilized. This hybrid phenotype can facilitate metabolic plasticity of cancer cells more specifically in metastasis and therapy-resistance. In light of the metabolic heterogeneity and plasticity of cancer cells that had until recently remained unappreciated, strategies targeting cancer metabolic dependency appear to be promising in the development of novel and effective cancer therapeutics.

中文翻译：

---

线粒体作为癌症的新兴治疗靶标。

线粒体由于其在细胞增殖和死亡中的关键作用而已成为重要的药理学靶标。在肿瘤组织中，线粒体可以转换代谢表型，以满足高能量需求和大分子合成的挑战。此外，线粒体可与肿瘤微环境发生串扰，并且来自与癌症相关的成纤维细胞的信号可撞击线粒体。癌细胞还可以获得杂合表型，其中可以同时利用糖酵解和氧化磷酸化（OXPHOS）。这种杂合表型可以促进癌细胞的代谢可塑性，尤其是在转移和抗药性方面。鉴于癌细胞的代谢异质性和可塑性直到最近才被人们所认识，